News headlines about Strongbridge Biopharma (NASDAQ:SBBP) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Strongbridge Biopharma earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.1850738738377 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of Strongbridge Biopharma (NASDAQ SBBP) traded up $0.10 during mid-day trading on Friday, reaching $8.00. The company had a trading volume of 265,474 shares, compared to its average volume of 181,960. The stock has a market cap of $282.92, a price-to-earnings ratio of -2.35 and a beta of 2.60. The company has a debt-to-equity ratio of -1.89, a current ratio of 4.70 and a quick ratio of 4.61. Strongbridge Biopharma has a one year low of $2.10 and a one year high of $8.85.

A number of brokerages recently issued reports on SBBP. BidaskClub upgraded Strongbridge Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Cantor Fitzgerald restated an “overweight” rating on shares of Strongbridge Biopharma in a research note on Wednesday, December 6th. Zacks Investment Research lowered Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, November 22nd. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Strongbridge Biopharma in a research note on Wednesday, November 15th. Finally, ValuEngine lowered Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Strongbridge Biopharma presently has an average rating of “Buy” and an average target price of $12.81.

TRADEMARK VIOLATION WARNING: This news story was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/strongbridge-biopharma-sbbp-earning-somewhat-positive-news-coverage-report-finds/1805838.html.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Insider Buying and Selling by Quarter for Strongbridge Biopharma (NASDAQ:SBBP)

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.